BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin ...

BioVersys & Shionogi ink global research collaboration for broad-spectrum NTM clinical candidate: Basel, Switzerland Thursday, July 3, 2025, 10:00 Hrs [IST] BioVersys AG, a multi- ...

Shionogi will pay BioVersys $6.3 million for developing BV500, BioVersys's drug candidate for non-tuberculous mycobacteria.

Swiss biopharma company BioVersys (today announced a research and exclusive license option agreement with the Japanese ...

Basel-based BioVersys stands to receive CHF 5 million upfront under the terms of the deal, which could be worth up to CHF 479 ...

Storied Japanese pharma Shionogi is upping its arsenal in the fight against antibiotic resistance. | Storied Japanese pharma ...

Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, July 02, 2025 (GLOBE NEWSWIRE) -- The Global Research Collaboration is a research and exclusive license option agreement with Shionogi to ...

OSAKA/TOKYO -- Japanese drugmaker Shionogi said Wednesday that it will acquire Torii Pharmaceutical and other assets from Japan Tobacco in a deal worth around 160 billion yen ($1.1 billion ...

Camping trash cans are integral to leaving no trace in the great outdoors—check out our top picks and find the right one for your next adventure.

The upgrade of Shionogi & Co. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

Shionogi plans to create its first U.S. discovery lab in San Diego, with a focus on antimicrobial and pandemic preparedness research as well as development of infectious disease treatments.

Shionogi’s Commitment to Fighting Antimicrobial Resistance Shionogi has a strong heritage in the field of anti-infectives and has been developing antimicrobial therapies for more than 60 years.